A chemist and biocompatibility expert offers the latest insights and predictions on medtech biocompatibility testing.
The Palo Alto, CA-based company will collaborate with Magic Leap, a specialist in augmented reality and spatial computer technology to bring its technology to an AR platform.
The Boulder, CO-based company has been granted a Breakthrough Device Designation for its liquid biopsy and tissue specimen assay.
A study from Mayo Clinic researchers shows less than two thirds of women ages 30 to 65 were up-to-date with cervical cancer screenings in 2016, which is below the 81% screening compliance rate self-reported in the 2015 National Health Interview Survey.
The two companies will look at advancing the development and commercialization of diagnostic tests for early detection of the disease.
The MPN method can be useful when traditional bioburden tests won’t work, but it must be clearly understood and carefully implemented.
Seven key trends and events helped make Liquid Biopsy attractive to investors, shareholders, patients, and physicians.
Researchers found that SelectMDx, a test for prostate cancer, had a cost-savings of $1,694 per patient.
Personal Genome Diagnostics received a breakthrough device designation from FDA for the PGDx elio plasma resolve liquid biopsy test.
Blue Earth Diagnostics shines at the 2018 annual meeting of the Society of Nuclear Medicine and Molecular Imaging, with fleshed out results from the LOCATE trial.